Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Ev
about
Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines.Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodiesProximal glycans outside of the epitopes regulate the presentation of HIV-1 envelope gp120 helper epitopesGene transfer in humans using a conditionally replicating lentiviral vectorHyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine designApproaches to preventative and therapeutic HIV vaccinesHarnessing the protective potential of HIV-1 neutralizing antibodiesPoxvirus vectors as HIV/AIDS vaccines in humansHIV-1 neutralizing antibodies: understanding nature's pathwaysAn anti-HIV-1 V3 loop antibody fully protects cross-clade and elicits T-cell immunity in macaques mucosally challenged with an R5 clade C SHIVAiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidatesStructure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1Structure-Based Design of a Protein Immunogen that Displays an HIV-1 gp41 Neutralizing EpitopeOuter Domain of HIV-1 gp120: Antigenic Optimization, Structural Malleability, and Crystal Structure with Antibody VRC-PG04Comparative immunogenicity of HIV-1 gp160, gp140 and gp120 expressed by live attenuated newcastle disease virus vectorHuman antibodies that neutralize HIV-1: identification, structures, and B cell ontogeniesPriming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responsesHuman immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodiesCurrent issues in the development of a vaccine to prevent human immunodeficiency virus: insights from the society of infectious diseases pharmacists.Comparison of immunogenicity between codon optimized HIV-1 Thailand subtype B gp140 and gp145 vaccines.An Enhanced Synthetic Multiclade DNA Prime Induces Improved Cross-Clade-Reactive Functional Antibodies when Combined with an Adjuvanted Protein Boost in Nonhuman Primates.Neutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140Solution structure, conformational dynamics, and CD4-induced activation in full-length, glycosylated, monomeric HIV gp120Identification and characterization of a peptide that specifically binds the human, broadly neutralizing anti-human immunodeficiency virus type 1 antibody b12B cell recognition of the conserved HIV-1 co-receptor binding site is altered by endogenous primate CD4.Anti-HIV-1 response elicited in rabbits by anti-idiotype monoclonal antibodies mimicking the CD4-binding siteEvolution of antibody landscape and viral envelope escape in an HIV-1 CRF02_AG infected patient with 4E10-like antibodies.A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolatesTiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies.Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variablesProtection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.Comparative immunogenicity of subtype a Human Immunodeficiency Virus type 1 envelope exhibiting differential exposure of conserved neutralization epitopesHIV neutralizing antibodies: clinical correlates and implications for vaccines.Characterization of gp120 and its single-chain derivatives, gp120-CD4D12 and gp120-M9: implications for targeting the CD4i epitope in human immunodeficiency virus vaccine design.Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies.Evidence that antibody-mediated neutralization of human immunodeficiency virus type 1 by sera from infected individuals is independent of coreceptor usageNeutralizing antibodies in sera from macaques infected with chimeric simian-human immunodeficiency virus containing the envelope glycoproteins of either a laboratory-adapted variant or a primary isolate of human immunodeficiency virus type 1.Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage.Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting.Study of the V3 loop as a target epitope for antibodies involved in the neutralization of primary isolates versus T-cell-line-adapted strains of human immunodeficiency virus type 1
P2860
Q24531479-DB2076E5-9E85-4FAC-9256-A023FD27E81AQ24561905-39A50C95-48FD-401C-B81C-C9C55C878889Q24645308-F3083648-2EF8-4790-8202-1D520DFF7118Q24675343-80D0A144-8AA4-43DC-8D1F-00C8E640C316Q24679395-4D99BE74-30E1-47D4-A48A-15E61C8AAF88Q26764851-C779409A-B792-401A-AA81-2E8EED30DD04Q26766153-48779468-CCF0-4F26-BC78-B48C9E7F6D78Q26995078-7121D36E-DBA8-4263-935F-089F5C951630Q27000480-CA643BC1-FEF0-477C-A82B-79798E32C38CQ27349203-D7F2FF66-7A25-4B4D-A321-6B020F64E0D8Q27489000-14D0537D-1626-4530-923F-73C7B7D469F4Q27662155-B1D69CE1-2A84-44E7-8181-3DB305A58C34Q27675260-AA165F02-5988-42D2-B571-03C8E125F8B7Q27675468-B64A7290-53D5-4DA6-A6A2-4E1B7BBACCB8Q28533970-BA8E7FA9-2B43-46DF-9863-9360AE5D2472Q28602877-69E10518-4AD6-435E-8177-5AFBBEC1CD49Q28749120-5C53B25A-EF85-4964-B47B-1BCF6ED7C2BBQ29619015-DE94E69B-9E2A-4C37-9780-035B66CD73E3Q30350731-BF1E5BA4-CD03-42ED-9733-CF2CEB1251DEQ30360326-2060AF2B-FC29-4D98-AB0A-DFBDD237EFFAQ30375785-21F69BC3-0B10-4940-8711-F9C20CD87C39Q30431941-BD5B64B5-56E6-4098-B796-7893FAE5C68DQ30524225-3D943237-14AF-40F7-9271-F6B384C4A43AQ30701127-461BD198-0AFB-4FCA-B7E9-9FB91D760AECQ33373664-8492CF62-C21B-43D0-AB2E-E3F1640162F7Q33377024-4E39DE5A-5712-4ABF-9E41-8BEC8830875FQ33518005-E2A5AD5D-87D2-444F-82C6-D265FC513B15Q33603494-8485B19B-0B9E-49AA-9260-46C0883DE375Q33614365-D46EEC1D-9086-458E-A935-A136309A5139Q33614495-FC0C69DC-844B-4364-93C6-A3F13679C3DFQ33647300-36DFA9F3-522D-49D8-A784-F151E3A35C63Q33648910-F0520B1F-7C6A-4C13-BC0E-ABB3E05E68CFQ33703451-D4936111-FB83-43C4-B6A4-1D8D614776CBQ33717477-E3456E4F-BC28-45D0-9286-EDE740D3F3A8Q33719511-D39BE04E-3203-4BA7-9998-8EDD855FFD0DQ33782296-9B549880-4897-4211-852A-4920927B571DQ33783516-CEA1E1C7-3E6C-437C-AF2E-E91BB6DE1028Q33783714-9FDBE656-F9F3-4A7F-BB6F-E3B271DFBF69Q33785383-B5976A52-4238-4D0D-8820-110C1C5AD3FAQ33786049-3458B2B0-B7A7-4601-A706-30E39EF6C637
P2860
Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Ev
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh-hant
name
Immunization with envelope sub ...... tious Diseases AIDS Vaccine Ev
@en
Immunization with envelope sub ...... tious Diseases AIDS Vaccine Ev
@nl
type
label
Immunization with envelope sub ...... tious Diseases AIDS Vaccine Ev
@en
Immunization with envelope sub ...... tious Diseases AIDS Vaccine Ev
@nl
prefLabel
Immunization with envelope sub ...... tious Diseases AIDS Vaccine Ev
@en
Immunization with envelope sub ...... tious Diseases AIDS Vaccine Ev
@nl
P2093
P356
P1476
Immunization with envelope sub ...... tious Diseases AIDS Vaccine Ev
@en
P2093
Clements ML
Mascola JR
McCutchan FE
P304
P356
10.1093/INFDIS/173.2.340
P407
P577
1996-02-01T00:00:00Z